Total Payments
$6.7M
2024 Payments
$231,814
Companies
10
Transactions
1,034
Medicare Patients
12,191
Medicare Billing
$275,856
Payment Breakdown by Category
Research$4.2M (62.7%)
Consulting$2.5M (37.3%)
Other$2,100 (0.0%)
Food & Beverage$214.21 (0.0%)
Travel$31.58 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $4.2M | 242 | 62.7% |
| Consulting Fee | $2.5M | 785 | 37.3% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $2,100 | 1 | 0.0% |
| Food and Beverage | $214.21 | 4 | 0.0% |
| Travel and Lodging | $31.58 | 2 | 0.0% |
Payments by Type
Research
$4.2M
242 transactions
General
$2.5M
792 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $3.5M | 144 | $0 (2024) |
| Merck Sharp & Dohme Corporation | $2.5M | 774 | $0 (2021) |
| Regeneron Pharmaceuticals, Inc. | $466,477 | 78 | $0 (2024) |
| Eli Lilly and Company | $165,240 | 19 | $0 (2024) |
| Avid Radiopharmaceuticals, Inc. | $64,000 | 1 | $0 (2021) |
| PFIZER INC. | $27,585 | 10 | $0 (2024) |
| Lilly USA, LLC | $5,057 | 5 | $0 (2017) |
| Abbott Laboratories | $38.30 | 1 | $0 (2022) |
| Siemens Medical Solutions USA, Inc. | $34.80 | 1 | $0 (2019) |
| GE HEALTHCARE | $16.11 | 1 | $0 (2019) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $231,814 | 53 | E.R. Squibb & Sons, L.L.C. ($150,949) |
| 2023 | $840,559 | 41 | E.R. Squibb & Sons, L.L.C. ($752,754) |
| 2022 | $525,753 | 43 | E.R. Squibb & Sons, L.L.C. ($432,566) |
| 2021 | $1.5M | 319 | Merck Sharp & Dohme Corporation ($953,916) |
| 2020 | $1.5M | 318 | Merck Sharp & Dohme Corporation ($810,558) |
| 2019 | $1.3M | 143 | E.R. Squibb & Sons, L.L.C. ($835,858) |
| 2018 | $628,664 | 64 | E.R. Squibb & Sons, L.L.C. ($402,200) |
| 2017 | $208,950 | 53 | Merck Sharp & Dohme Corporation ($198,636) |
All Payment Transactions
1,034 individual payment records from CMS Open Payments — Page 1 of 42
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/12/2024 | PFIZER INC. | — | Consulting Fee | Cash or cash equivalent | $3,000.00 | General |
| 11/26/2024 | Regeneron Pharmaceuticals, Inc. | LIBTAYO (Biological) | — | Cash or cash equivalent | $480.00 | Research |
| Study: A TWO-PART RANDOMIZED, PHASE 3 STUDY OF COMBINATIONS OF CEMIPLIMAB (ANTI-PD-1 ANTIBODY) AND PLATINUM-BASED DOUBLET CHEMOTHERAPY IN FIRST-LINE TREATMENT OF PATIENTS WITH ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER • Category: ONCOLOGY | ||||||
| 11/21/2024 | PFIZER INC. | — | Consulting Fee | Cash or cash equivalent | $6,120.00 | General |
| 10/30/2024 | Regeneron Pharmaceuticals, Inc. | LIBTAYO (Biological) | — | Cash or cash equivalent | $660.00 | Research |
| Study: A TWO-PART RANDOMIZED, PHASE 3 STUDY OF COMBINATIONS OF CEMIPLIMAB (ANTI-PD-1 ANTIBODY) AND PLATINUM-BASED DOUBLET CHEMOTHERAPY IN FIRST-LINE TREATMENT OF PATIENTS WITH ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER • Category: ONCOLOGY | ||||||
| 10/23/2024 | PFIZER INC. | — | Consulting Fee | Cash or cash equivalent | $4,140.00 | General |
| 09/20/2024 | PFIZER INC. | — | Consulting Fee | Cash or cash equivalent | $2,640.00 | General |
| 08/28/2024 | PFIZER INC. | — | Consulting Fee | Cash or cash equivalent | $2,880.00 | General |
| 08/28/2024 | Regeneron Pharmaceuticals, Inc. | LIBTAYO (Biological) | — | Cash or cash equivalent | $360.00 | Research |
| Study: A TWO-PART RANDOMIZED, PHASE 3 STUDY OF COMBINATIONS OF CEMIPLIMAB (ANTI-PD-1 ANTIBODY) AND PLATINUM-BASED DOUBLET CHEMOTHERAPY IN FIRST-LINE TREATMENT OF PATIENTS WITH ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER • Category: ONCOLOGY | ||||||
| 07/18/2024 | PFIZER INC. | — | Consulting Fee | Cash or cash equivalent | $5,220.00 | General |
| 07/18/2024 | Regeneron Pharmaceuticals, Inc. | LIBTAYO (Biological) | — | Cash or cash equivalent | $2,800.00 | Research |
| Study: A GLOBAL, RANDOMISED, PHASE 3, OPEN-LABEL STUDY OF REGN2810 (ANTI-PD 1 ANTIBODY) VERSUS PLATINUM BASED CHEMOTHERAPY IN FIRST LINE TREATMENT OF PATIENTS WITH ADVANCED OR METASTATIC PD L1+NON-SMALL CELL LUNG CANCER • Category: ONCOLOGY | ||||||
| 06/21/2024 | Regeneron Pharmaceuticals, Inc. | LIBTAYO (Biological) | — | Cash or cash equivalent | $6,475.00 | Research |
| Study: A GLOBAL, RANDOMISED, PHASE 3, OPEN-LABEL STUDY OF REGN2810 (ANTI-PD 1 ANTIBODY) VERSUS PLATINUM BASED CHEMOTHERAPY IN FIRST LINE TREATMENT OF PATIENTS WITH ADVANCED OR METASTATIC PD L1+NON-SMALL CELL LUNG CANCER • Category: ONCOLOGY | ||||||
| 06/21/2024 | Regeneron Pharmaceuticals, Inc. | LIBTAYO (Biological) | — | Cash or cash equivalent | $600.00 | Research |
| Study: A TWO-PART RANDOMIZED, PHASE 3 STUDY OF COMBINATIONS OF CEMIPLIMAB (ANTI-PD-1 ANTIBODY) AND PLATINUM-BASED DOUBLET CHEMOTHERAPY IN FIRST-LINE TREATMENT OF PATIENTS WITH ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER • Category: ONCOLOGY | ||||||
| 06/13/2024 | PFIZER INC. | — | Consulting Fee | Cash or cash equivalent | $1,380.00 | General |
| 06/06/2024 | PFIZER INC. | — | Consulting Fee | Cash or cash equivalent | $780.00 | General |
| 06/05/2024 | E.R. Squibb & Sons, L.L.C. | — | — | Cash or cash equivalent | $75.00 | Research |
| Study: A Study of BMS-986315 and Nivolumab in Combination With Chemotherapy in Participants With First-line Stage IV or Recurrent nsclc | ||||||
| 06/05/2024 | Eli Lilly and Company | — | — | Cash or cash equivalent | $75.00 | Research |
| Study: A PHASE 2 STUDY OF ORAL SELPERCATINIB (LOXO-292) IN PATIENTS WITH ADVANCED SOLID TUMORS, INCLUDING REARRANGED IN TRANSFECTION (RET) FUSION-POSITIVE SOLID TUMORS, MEDULLARY THYROID CANCER AND OTHER TUMORS WITH RET ACTIVATION | ||||||
| 05/16/2024 | Regeneron Pharmaceuticals, Inc. | LIBTAYO (Biological) | — | Cash or cash equivalent | $540.00 | Research |
| Study: A TWO-PART RANDOMIZED, PHASE 3 STUDY OF COMBINATIONS OF CEMIPLIMAB (ANTI-PD-1 ANTIBODY) AND PLATINUM-BASED DOUBLET CHEMOTHERAPY IN FIRST-LINE TREATMENT OF PATIENTS WITH ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER • Category: ONCOLOGY | ||||||
| 05/10/2024 | Regeneron Pharmaceuticals, Inc. | LIBTAYO (Biological) | — | Cash or cash equivalent | $875.00 | Research |
| Study: A GLOBAL, RANDOMISED, PHASE 3, OPEN-LABEL STUDY OF REGN2810 (ANTI-PD 1 ANTIBODY) VERSUS PLATINUM BASED CHEMOTHERAPY IN FIRST LINE TREATMENT OF PATIENTS WITH ADVANCED OR METASTATIC PD L1+NON-SMALL CELL LUNG CANCER • Category: ONCOLOGY | ||||||
| 05/10/2024 | Regeneron Pharmaceuticals, Inc. | LIBTAYO (Biological) | — | Cash or cash equivalent | $720.00 | Research |
| Study: A TWO-PART RANDOMIZED, PHASE 3 STUDY OF COMBINATIONS OF CEMIPLIMAB (ANTI-PD-1 ANTIBODY) AND PLATINUM-BASED DOUBLET CHEMOTHERAPY IN FIRST-LINE TREATMENT OF PATIENTS WITH ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER • Category: ONCOLOGY | ||||||
| 05/08/2024 | Eli Lilly and Company | — | — | Cash or cash equivalent | $13,095.00 | Research |
| Study: LIBRETTO-432: A PLACEBO-CONTROLLED DOUBLE-BLINDED RANDOMIZED PHASE 3 STUDY OF ADJUVANT SELPERCATINIB FOLLOWING DEFINITIVE LOCOREGIONAL TREATMENT IN PARTICIPANTS WITH STAGE IB-IIIA RET FUSION-POSITIVE NSCLC | ||||||
| 05/08/2024 | E.R. Squibb & Sons, L.L.C. | — | — | Cash or cash equivalent | $75.00 | Research |
| Study: A Study to Compare the Efficacy and Safety of Lisocabtagene Maraleucel vs Investigator's Choice Options in Adult Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma | ||||||
| 05/08/2024 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | — | Cash or cash equivalent | $56.25 | Research |
| Study: Phase IIB Signal Detection Single arm, PD-1 (TNBC, SCLC, pancreatic, gastric, bladder, Ovarian) Mono and Combo • Category: Oncology | ||||||
| 05/02/2024 | PFIZER INC. | — | Consulting Fee | Cash or cash equivalent | $540.00 | General |
| 04/05/2024 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | — | Cash or cash equivalent | $75.00 | Research |
| Study: A phase III randomized, double-blind, multi-center study of adjuvant nivolumab versus placebo in subjects with high risk invasive urothelial carcinoma • Category: Oncology | ||||||
| 04/04/2024 | Regeneron Pharmaceuticals, Inc. | LIBTAYO (Biological) | — | Cash or cash equivalent | $350.00 | Research |
| Study: A GLOBAL, RANDOMISED, PHASE 3, OPEN-LABEL STUDY OF REGN2810 (ANTI-PD 1 ANTIBODY) VERSUS PLATINUM BASED CHEMOTHERAPY IN FIRST LINE TREATMENT OF PATIENTS WITH ADVANCED OR METASTATIC PD L1+NON-SMALL CELL LUNG CANCER • Category: ONCOLOGY | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| Phase III 1L Gastric nivo ipi vs nivo CT vs CT | E.R. Squibb & Sons, L.L.C. | $441,510 | 5 |
| Phase III 1L Metastatic RCC Nivo Ipi Cabo | E.R. Squibb & Sons, L.L.C. | $226,073 | 5 |
| Phase III 1L NSCLC nivo ipi chemo vs chemo in PDL-1 all comers | E.R. Squibb & Sons, L.L.C. | $198,420 | 4 |
| Phase III 1L Esophageal Nivo Ipi vs Nivo CT vs CT | E.R. Squibb & Sons, L.L.C. | $185,130 | 5 |
| A GLOBAL, RANDOMISED, PHASE 3, OPEN-LABEL STUDY OF REGN2810 ANTI-PD 1 ANTIBODY VERSUS PLATINUM BASED CHEMOTHERAPY IN FIRST LINE TREATMENT OF PATIENTS WITH ADVANCED OR METASTATIC PD L1NON-SMALL CELL LUNG CANCER | Regeneron Pharmaceuticals, Inc. | $170,414 | 13 |
| Phase III Stage III Unresectable NSCLC Combo - A Phase 3, Randomized, Open-Label Study to Compare Nivolumab Plus Concurrent Chemoradiotherapy (CCRT) followed by Nivolumab plus Ipilimumab or Nivolumab plus CCRT Followed by Nivolumab vs CCRT followed by Dur | E.R. Squibb & Sons, L.L.C. | $165,474 | 3 |
| A TWO-PART RANDOMIZED, PHASE 3 STUDY OF COMBINATIONS OF CEMIPLIMAB (ANTI-PD-1 ANTIBODY) AND PLATINUM-BASED DOUBLET CHEMOTHERAPY IN FIRST-LINE TREATMENT OF PATIENTS WITH ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER | Regeneron Pharmaceuticals, Inc. | $163,742 | 37 |
| Phase III Adjuvant HCC (mono vs placebo) | E.R. Squibb & Sons, L.L.C. | $156,486 | 2 |
| Phase III Nivo Ipi vs Placebo in Adjuvant RCC | E.R. Squibb & Sons, L.L.C. | $154,455 | 4 |
| Phase IIB Colon Cancer MSI nivo mono and combo | E.R. Squibb & Sons, L.L.C. | $150,744 | 5 |
| Phase III Adjuvant HCC mono vs placebo | E.R. Squibb & Sons, L.L.C. | $132,390 | 4 |
| A GLOBAL, RANDOMISED, PHASE 3, OPEN-LABEL STUDY OF REGN2810 (ANTI-PD 1 ANTIBODY) VERSUS PLATINUM BASED CHEMOTHERAPY IN FIRST LINE TREATMENT OF PATIENTS WITH ADVANCED OR METASTATIC PD L1+NON-SMALL CELL LUNG CANCER | Regeneron Pharmaceuticals, Inc. | $131,114 | 27 |
| Phase III Neoadjuvant NSCLC nivo chemo | E.R. Squibb & Sons, L.L.C. | $121,529 | 4 |
| Phase IIB MSI High CRC PMR | E.R. Squibb & Sons, L.L.C. | $92,595 | 3 |
| Phase III Nivo Ipi Combo in 1L Bladder | E.R. Squibb & Sons, L.L.C. | $90,330 | 3 |
| Phase III MSI High CRC (142 PMR) - A Phase 3 Randomized Clinical Trial of Nivolumab alone, Nivolumab in Combination with Ipilimumab, or an Investigator s Choice Chemotherapy in Participants with Microsatellite Instability High (MSI-H) or Mismatch Repair D | E.R. Squibb & Sons, L.L.C. | $82,875 | 2 |
| Phase III Peri-Adjuvant NSCLC Nivo Mono - A Phase 3, Randomized, Double-blind Study of Neoadjuvant Chemotherapy plus Nivolumab versus Neoadjuvant Chemotherapy plus Placebo, followed by Surgical Resection and Adjuvant Treatment with Nivolumab or Placebo fo | E.R. Squibb & Sons, L.L.C. | $82,500 | 3 |
| Phase III Nivo+Ipi vs Placebo in Adjuvant RCC (Part B FA) - A Phase 3 Randomized, Double-Blind Study of Nivolumab Monotherapy or Nivolumab Combined with Ipilimumab vs Placebo in Participants with Localized Renal Cell Carcinoma Who Underwent Radical or Par | E.R. Squibb & Sons, L.L.C. | $78,270 | 2 |
| Phase IIA Nivo in HL Pediatric nivo bv | E.R. Squibb & Sons, L.L.C. | $76,275 | 4 |
| Phase IIB Signal Detection Single arm, PD-1 TNBC, SCLC, pancreatic, gastric, bladder, Ovarian Mono and Combo | E.R. Squibb & Sons, L.L.C. | $75,838 | 3 |
| Phase III Nivo Ipi vs Placebo in Adjuvant RCC - A Phase 3 Randomized, Double-Blind Study of Nivolumab Monotherapy or Nivolumab Combined with Ipilimumab vs Placebo in Participants with Localized Renal Cell Carcinoma Who Underwent Radical or Partial Nephrec | E.R. Squibb & Sons, L.L.C. | $72,360 | 1 |
| Ph III MIBC Neoadjuvant 1L Bladder IDO + Nivo + chemo (FA-EFS & IA2-OS) | E.R. Squibb & Sons, L.L.C. | $61,575 | 1 |
| Phase III MSS 3L CRC Rela+Nivo vs. regorafenib/TAS-102 - A Phase III, Randomized, Sponsor Blinded Study of Relatlimab-Nivolumab Fixed Dosed Combination versus Regorafenib or Trifluridine plus Tipiracil for Participants with Later-Lines of Metastatic Color | E.R. Squibb & Sons, L.L.C. | $57,015 | 2 |
| Phase IIIB MSI High CRC PMR - A Phase 3 Randomized Clinical Trial of Nivolumab alone, Nivolumab in Combination with Ipilimumab, or an Investigator s Choice Chemotherapy in Participants with Microsatellite Instability High (MSI-H) or Mismatch Repair Defici | E.R. Squibb & Sons, L.L.C. | $55,680 | 1 |
| Ph III Nivo SC in previosly treated adv or met clear RCC - A Phase 3, Open-label, Randomized, Noninferiority Trial of the Subcutaneous Formulation of Nivolumab Versus Intravenous Nivolumab in Participants With Advanced or Metastatic Clear Cell Renal Cell | E.R. Squibb & Sons, L.L.C. | $52,665 | 2 |
| Phase III Randomized Study of Opdivo+Doc vs Doc in chemo-nave mCRPC (FA-OS) | E.R. Squibb & Sons, L.L.C. | $48,495 | 1 |
| Phase III Adjuvant Bladder nivo mono | E.R. Squibb & Sons, L.L.C. | $43,755 | 2 |
| Phase I IIA FIH Nivo Combination with Monotherapy Run-in | E.R. Squibb & Sons, L.L.C. | $41,100 | 3 |
| A STUDY OF SELPERCATINIB (LY3527723) IN PARTICIPANTS WITH ADVANCED OR METASTATIC RET FUSION-POSITIVE NON-SMALL CELL LUNG CANCER (LIBRETTO-431) | Eli Lilly and Company | $40,215 | 2 |
| Phase IIB Signal Detection Single arm PD 1 TNBC SCLC pancreatic gastric bladder Ovarian Mono and Combo | E.R. Squibb & Sons, L.L.C. | $39,025 | 1 |
| Phase IIB 1L NSCLC nivo ipi and nivo ipi chemo | E.R. Squibb & Sons, L.L.C. | $37,100 | 4 |
| Ph III MIBC Neoadjuvant 1L Bladder IDO Nivo chemo | E.R. Squibb & Sons, L.L.C. | $36,735 | 4 |
| A MULTICENTER, RANDOMIZED, OPEN LABEL, PHASE 3 TRIAL COMPARING SELPERCATINIB TO PHYSICIANS CHOICE OF CABOZANTINIB OR VANDETANIB IN PATIENTS WITH PROGRESSIVE, ADVANCED, KINASE INHIBITOR NAIVE, RET MUTANT MEDULLARY THYROID CANCER (LIBRETTO 531) | Eli Lilly and Company | $36,570 | 4 |
| Phase III Randomized Study of Opdivo Doc vs Doc in chemo CRPC | E.R. Squibb & Sons, L.L.C. | $32,295 | 1 |
| Phase III Nivo+Ipi Combo in 1L Bladder (FA = OS Primary Study Cis-Ineligible) | E.R. Squibb & Sons, L.L.C. | $29,610 | 2 |
| Multi Center Phase II Open Label Study to Evaluate Safety and Efficacy in Subjects with Melanoma Metastatic to the Brain Treated with Nivolumab in Combinatiion with Ipilimumab followed by Nivolumab Monotherapy | E.R. Squibb & Sons, L.L.C. | $29,280 | 1 |
| A MULTICENTER RANDOMIZED OPEN LABEL PHASE 3 TRIAL COMPARING SELPERCATINIB TO PHYSICIANS CHOICE OF CABOZANTINIB OR VANDETANIB IN PATIENTS WITH PROGRESSIVE ADVANCED KINASE INHIBITOR NAIVE RET MUTANT MEDULLARY THYROID CANCER (LIBRETTO 531) | Eli Lilly and Company | $28,470 | 1 |
| Phase III 1L Metastatic RCC Nivo/Ipi/Cabo | E.R. Squibb & Sons, L.L.C. | $26,370 | 2 |
| Phase III Nivo Ipi Combo in 1L Bladder FA OS nivo CT Substudy | E.R. Squibb & Sons, L.L.C. | $25,650 | 1 |
| Phase I IIA FIH Nivo Combination with Monotherapy Run in | E.R. Squibb & Sons, L.L.C. | $23,850 | 1 |
| Phase III 1L NSCLC nivo ipi chemo vs chemo in PDL 1 all comers | E.R. Squibb & Sons, L.L.C. | $21,690 | 1 |
| Ph III MIBC Neoadjuvant 1L Bladder IDO + Nivo + chemo (FA-EFS & IA2-OS & 9th DMC) | E.R. Squibb & Sons, L.L.C. | $20,955 | 1 |
| Phase III Neoadjuvant NSCLC nivo+chemo - Randomized, Open-Label, Phase 3 Trial of Nivolumab plus Ipilimumab or Nivolumab plus Platinum-Doublet Chemotherapy versus Platinum-Doublet Chemotherapy in Early Stage NSCLC | E.R. Squibb & Sons, L.L.C. | $20,565 | 2 |
| Phase III Stage III Unresectable NSCLC Combo | E.R. Squibb & Sons, L.L.C. | $19,740 | 3 |
| I-O CC Seattle Genetics Phase IIa combo in NHL nivo brentuximab | E.R. Squibb & Sons, L.L.C. | $19,725 | 3 |
| A PHASE 2 STUDY OF ORAL SELPERCATINIB (LOXO-292) IN PATIENTS WITH ADVANCED SOLID TUMORS INCLUDING REARRANGED IN TRANSFECTION (RET) FUSION-POSITIVE SOLID TUMORS MEDULLARY THYROID CANCER AND OTHER TUMORS WITH RET ACTIVATION | Eli Lilly and Company | $19,275 | 1 |
| Phase III 1L NSCLC nivo+ipi+chemo vs chemo in PDL-1 all comers | E.R. Squibb & Sons, L.L.C. | $18,765 | 2 |
| OUTREACH 3L+ LBCL 017007 - A Safety Trial of Lisocabtagene Maraleucel (JCAR017) for Relapsed and Refractory (R/R) B-cell Non-Hodgkin Lymphoma (NHL) in the Outpatient Setting | E.R. Squibb & Sons, L.L.C. | $18,105 | 1 |
| Phase III Neoadjuvant NSCLC nivo chemo - Randomized, Open-Label, Phase 3 Trial of Nivolumab plus Ipilimumab or Nivolumab plus Platinum-Doublet Chemotherapy versus Platinum-Doublet Chemotherapy in Early Stage NSCLC | E.R. Squibb & Sons, L.L.C. | $18,075 | 1 |
| Phase III 1L Gastric (nivo+ipi vs nivo+CT vs CT) | E.R. Squibb & Sons, L.L.C. | $17,250 | 2 |
| Multi-Center Phase II Open-Label Study to Evaluate Safety and Efficacy in Subjects with Melanoma Metastatic to the Brain Treated with Nivolumab in Combinatiion with Ipilimumab followed by Nivolumab Monotherapy | E.R. Squibb & Sons, L.L.C. | $16,650 | 3 |
| Phase III Randomized Study of Opdivo+Doc vs Doc in chemo-nave mCRPC | E.R. Squibb & Sons, L.L.C. | $16,170 | 2 |
| LIBRETTO-431: A MULTICENTER, RANDOMIZED, OPEN-LABEL, PHASE 3 TRIAL COMPARING LOXO-292 TO PLATINUM-BASED AND PEMETREXED THERAPY WITH OR WITHOUT PEMBROLIZUMAB AS INITIAL TREATMENT OF ADVANCED OR METASTATIC RET FUSION-POSITIVE NON-SMALL CELL LUNG CANCER | Eli Lilly and Company | $16,005 | 3 |
| Phase II Nivo orc Nivo combo in mCRC MSI-H & non MSI-H - A Phase 2 Clinical Trial of Nivolumab, or Nivolumab Combinations in Recurrent and Metastatic Microsatellite Instability High (MSI-H) and Non-MSI-H Colon Cancer | E.R. Squibb & Sons, L.L.C. | $13,869 | 2 |
| LIBRETTO-432: A PLACEBO-CONTROLLED DOUBLE-BLINDED RANDOMIZED PHASE 3 STUDY OF ADJUVANT SELPERCATINIB FOLLOWING DEFINITIVE LOCOREGIONAL TREATMENT IN PARTICIPANTS WITH STAGE IB-IIIA RET FUSION-POSITIVE NSCLC | Eli Lilly and Company | $13,170 | 2 |
| PhII 1L HCC Rela+Nivo+Bev vs Nivo+Bev - A Phase 1/2, Safety Confirmation, Placebo-controlled, Randomized Study of Nivolumab in Combination with Relatlimab and Bevacizumab in Treatment-naive Advanced/Metastatic Hepatocellular Carcinoma | E.R. Squibb & Sons, L.L.C. | $11,007 | 2 |
| Phase IIA Nivo in HL Pediatric (nivo+bv) - Risk-based, response-adapted, Phase II open-label trial of nivolumab + brentuximab vedotin (N + Bv) for children, adolescents, and young adults with relapsed/refractory (R/R) CD30 + classic Hodgkin lymphoma (cHL) | E.R. Squibb & Sons, L.L.C. | $7,650 | 2 |
| Ph III MIBC (Nivo/NKTR vs Nivo mono) - A Phase 3, Randomized, Study of Neoadjuvant and Adjuvant Nivolumab Plus Bempegaldesleukin (NKTR-214), Versus Nivolumab Alone Versus Standard of Care in Participants with Muscle-Invasive Bladder Cancer (MIBC) Who Are | E.R. Squibb & Sons, L.L.C. | $7,620 | 1 |
| Ph III MIBC Nivo NKTR vs Nivo mono - A Phase 3, Randomized, Study of Neoadjuvant and Adjuvant Nivolumab Plus Bempegaldesleukin (NKTR-214), Versus Nivolumab Alone Versus Standard of Care in Participants with Muscle-Invasive Bladder Cancer (MIBC) Who Are Ci | E.R. Squibb & Sons, L.L.C. | $7,455 | 1 |
| A PHASE 2 STUDY OF ORAL SELPERCATINIB (LOXO-292) IN PATIENTS WITH ADVANCED SOLID TUMORS, INCLUDING REARRANGED IN TRANSFECTION (RET) FUSION-POSITIVE SOLID TUMORS, MEDULLARY THYROID CANCER AND OTHER TUMORS WITH RET ACTIVATION | Eli Lilly and Company | $7,335 | 4 |
| Phase III 1L Esophageal (Nivo+Ipi vs Nivo+CT vs CT) | E.R. Squibb & Sons, L.L.C. | $7,125 | 2 |
| Ph III Nivo SC in previosly treated adv or met clear RCC with Biocomparability Study - A Phase 3, Open-label, Randomized, Noninferiority Trial of the Subcutaneous Formulation of Nivolumab Versus Intravenous Nivolumab in Participants With Advanced or Metas | E.R. Squibb & Sons, L.L.C. | $6,120 | 1 |
| Phase III Peri-Adjuvant NSCLC Nivo Mono | E.R. Squibb & Sons, L.L.C. | $6,030 | 2 |
| Phase IIA Nivo in HL Pediatric nivo bv - Risk-based, response-adapted, Phase II open-label trial of nivolumab + brentuximab vedotin (N + Bv) for children, adolescents, and young adults with relapsed/refractory (R/R) CD30 + classic Hodgkin lymphoma (cHL) a | E.R. Squibb & Sons, L.L.C. | $5,700 | 1 |
| Phase IIB 1L NSCLC nivo ipi and nivo ipi chemo - A Study of Nivolumab in Combination with Ipilimumab (part 1); and Nivolumab plus Ipilimumab in Combination with Chemotherapy (part 2) as First Line Therapy in Stage IV Non- Small Cell Lung Cancer (NSCLC) | E.R. Squibb & Sons, L.L.C. | $4,800 | 1 |
| A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF RAMUCIRUMAB PLUS DOCETAXEL VERSUS PLACEBO PLUS DOCETAXEL IN PATIENTS WITH LOCALLY ADVANCED OR UNRESECTABLE OR METASTATIC UROTHELIAL CARCINOMA WHO PROGRESSED ON OR AFTER PLATINUM-BASED THERAPY | Eli Lilly and Company | $4,200 | 2 |
| Phase IIA CTLA4 NF Randomized chemo combo study in mCRPC - A Phase 2, Open-label, Randomized Controlled Trial of BMS-986218 or BMS-986218 Plus Nivolumab in Combination With Docetaxel in Participants With Metastatic Castration-resistant Prostate Cancer | E.R. Squibb & Sons, L.L.C. | $1,830 | 3 |
| Progressive Combinations- Metastatic ER HER2- Breast Cancer | E.R. Squibb & Sons, L.L.C. | $1,675 | 1 |
| A Global, Randomised, Phase 3, Open-label Study of REGN2810 ANTI-PD 1 Antibody Versus Platinum Based Chemotherapy in First Line Treatment of Patients With Advanced or Metastatic PD L1Non-small Cell Lung Cancer | Regeneron Pharmaceuticals, Inc. | $1,208 | 1 |
| Ph III MIBC (Nivo/NKTR vs Nivo mono) | E.R. Squibb & Sons, L.L.C. | $1,035 | 1 |
| Ph I/II Japan r/r TCL Monotherapy - A Phase 1/2 Study of the Safety, Tolerability, Pharmacokinetics, and Efficacy of BMS-986369 in Participants with Relapsed or Refractory T-cell Lymphomas in Japan | E.R. Squibb & Sons, L.L.C. | $630.00 | 1 |
| Phase I JNK1 Monotherapy/Combination - A Phase 1, Open-label, Multicenter Study of BMS-986360/CC-90001 Alone and in Combination with Chemotherapy or Nivolumab in Advanced Solid Tumors | E.R. Squibb & Sons, L.L.C. | $375.00 | 1 |
| Phase III MSS 3L CRC Rela and Nivo vs regorafenib-TAS-102 - A Phase III, Randomized, Sponsor Blinded Study of Relatlimab-Nivolumab Fixed Dosed Combination versus Regorafenib or Trifluridine plus Tipiracil for Participants with Later-Lines of Metastatic Co | E.R. Squibb & Sons, L.L.C. | $150.00 | 1 |
| Phase IIB Signal Detection Single arm, PD-1 (TNBC, SCLC, pancreatic, gastric, bladder, Ovarian) Mono and Combo | E.R. Squibb & Sons, L.L.C. | $112.50 | 2 |
| A Study of BMS-986315 and Nivolumab in Combination With Chemotherapy in Participants With First-line Stage IV or Recurrent nsclc | E.R. Squibb & Sons, L.L.C. | $75.00 | 1 |
| A Study to Compare the Efficacy and Safety of Lisocabtagene Maraleucel vs Investigator's Choice Options in Adult Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma | E.R. Squibb & Sons, L.L.C. | $75.00 | 1 |
| A phase III randomized, double-blind, multi-center study of adjuvant nivolumab versus placebo in subjects with high risk invasive urothelial carcinoma | E.R. Squibb & Sons, L.L.C. | $75.00 | 1 |
| I-O CC Seattle Genetics Phase IIa combo in NHL nivo brentuximab - A Phase I/ II Study to Evaluate the Safety and Preliminary Efficacy of Nivolumab in Combination with Brentuximab Vedotin in Subjects with Relapsed Refractory Non Hodgkin Lymphomas with CD30 | E.R. Squibb & Sons, L.L.C. | $75.00 | 1 |
| Phase I II FIH STING Monotherapy Combination in advanced solid tumors | E.R. Squibb & Sons, L.L.C. | $75.00 | 1 |
| Phase I/II FIH STING Monotherapy/Combination in advanced solid tumors | E.R. Squibb & Sons, L.L.C. | $75.00 | 1 |
| Phase III Adjuvant Bladder (nivo mono) | E.R. Squibb & Sons, L.L.C. | $75.00 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 14 | 3,818 | 3,832 | $354,789 | $70,874 |
| 2022 | 24 | 2,866 | 2,875 | $311,961 | $61,304 |
| 2021 | 38 | 2,346 | 2,382 | $369,942 | $60,345 |
| 2020 | 41 | 3,161 | 3,246 | $545,318 | $83,333 |
Total Patients
12,191
Total Services
12,335
Medicare Billing
$275,856
Procedure Codes
130
All Medicare Procedures & Services
130 procedure records from CMS Medicare Utilization — Page 1 of 6
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 78815 | Nuclear medicine study from skull base to mid-thigh with ct scan | Office | 2023 | 256 | 265 | $123,490 | $22,471 | 18.2% |
| 77080 | Dxa bone density measurement of hip, pelvis, spine | Office | 2023 | 1,601 | 1,601 | $62,439 | $14,746 | 23.6% |
| 77080 | Dxa bone density measurement of hip, pelvis, spine | Facility | 2023 | 1,411 | 1,411 | $55,029 | $13,310 | 24.2% |
| 78815 | Nuclear medicine study from skull base to mid-thigh with ct scan | Facility | 2023 | 71 | 75 | $34,950 | $6,438 | 18.4% |
| 78306 | Nuclear medicine study of bone and/or joint whole body | Facility | 2023 | 70 | 70 | $11,130 | $2,000 | 18.0% |
| 76770 | Complete ultrasound scan behind abdominal cavity | Facility | 2023 | 83 | 83 | $11,620 | $1,950 | 16.8% |
| 78816 | Nuclear medicine study whole body with ct scan | Office | 2023 | 20 | 20 | $9,420 | $1,763 | 18.7% |
| 78582 | Nuclear medicine study of lung ventilation and circulation | Facility | 2023 | 42 | 42 | $8,694 | $1,554 | 17.9% |
| 78264 | Nuclear medicine study of stomach to assess emptying | Facility | 2023 | 51 | 51 | $7,599 | $1,469 | 19.3% |
| 76700 | Complete ultrasound scan of abdomen | Facility | 2023 | 32 | 32 | $4,928 | $903.89 | 18.3% |
| 78227 | Nuclear medicine study of liver and bile duct system with use of drugs | Facility | 2023 | 25 | 25 | $4,325 | $728.84 | 16.9% |
| 76705 | Limited ultrasound scan of abdomen | Facility | 2023 | 32 | 32 | $3,552 | $620.39 | 17.5% |
| 76536 | Ultrasound scan of head and neck soft tissue | Facility | 2023 | 35 | 35 | $3,745 | $620.10 | 16.6% |
| 78071 | Nuclear medicine study of parathyroid with spect | Facility | 2023 | 17 | 17 | $3,774 | $571.34 | 15.1% |
| 76770 | Complete ultrasound scan behind abdominal cavity | Office | 2023 | 24 | 25 | $3,500 | $561.05 | 16.0% |
| 78803 | Nuclear medicine study, spect imaging, 1 area or single acquisition, single day imaging | Facility | 2023 | 11 | 11 | $2,167 | $428.57 | 19.8% |
| 76700 | Complete ultrasound scan of abdomen | Office | 2023 | 13 | 13 | $2,002 | $385.71 | 19.3% |
| 76536 | Ultrasound scan of head and neck soft tissue | Office | 2023 | 13 | 13 | $1,391 | $189.36 | 13.6% |
| 78014 | Nuclear medicine study of thyroid and thyroid function | Facility | 2023 | 11 | 11 | $1,034 | $163.87 | 15.8% |
| 78815 | Nuclear medicine study from skull base to mid-thigh with ct scan | Office | 2022 | 138 | 140 | $65,240 | $11,770 | 18.0% |
| 77080 | Dxa bone density measurement of hip, pelvis, spine | Office | 2022 | 921 | 921 | $35,919 | $8,683 | 24.2% |
| 77080 | Dxa bone density measurement of hip, pelvis, spine | Facility | 2022 | 824 | 825 | $32,175 | $8,001 | 24.9% |
| 74177 | Ct scan of abdomen and pelvis with contrast | Facility | 2022 | 57 | 58 | $20,010 | $3,519 | 17.6% |
| 76770 | Complete ultrasound scan behind abdominal cavity | Facility | 2022 | 137 | 137 | $19,180 | $3,498 | 18.2% |
| 74176 | Ct scan of abdomen and pelvis without contrast | Facility | 2022 | 46 | 46 | $15,180 | $2,980 | 19.6% |
About Dr. Rajan Agarwal, MD
Dr. Rajan Agarwal, MD is a Nuclear Radiology healthcare provider based in Abington, Pennsylvania. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 01/09/2007. The National Provider Identifier (NPI) number assigned to this provider is 1871642017.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Rajan Agarwal, MD has received a total of $6.7M in payments from pharmaceutical and medical device companies, with $231,814 received in 2024. These payments were reported across 1,034 transactions from 10 companies. The most common payment nature is "" ($4.2M).
As a Medicare-enrolled provider, Agarwal has provided services to 12,191 Medicare beneficiaries, totaling 12,335 services with total Medicare billing of $275,856. Data is available for 4 years (2020–2023), covering 130 distinct procedure/service records.
Ad
Practice Information
- Specialty Nuclear Radiology
- Other Specialties Diagnostic Radiology
- Location Abington, PA
- Active Since 01/09/2007
- Last Updated 04/22/2015
- Taxonomy Code 2085N0904X
- Entity Type Individual
- NPI Number 1871642017
Products in Payments
- OPDIVO (Biological) $3.2M
- KEYTRUDA (Biological) $1.9M
- LIBTAYO (Biological) $451,085
- LENVIMA (Drug) $342,620
- MK-7339 (Drug) $92,483
- OPDUALAG (Drug) $68,022
- WELIREG (Drug) $42,255
- LIBTAYO CEMIPLIMAB-RWLC INJECTION (Biological) $14,184
- AMYVID (Drug) $5,057
- CYRAMZA (Drug) $4,200
- MK-6482 (Drug) $3,390
- MK-1308 (Drug) $3,000
- MK-8931 (Drug) $100.00
- CONFIRM RX (Device) $38.30
- Software and Accessories (Device) $34.80
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.